Bio

James (Jim) Gale is the founding partner of Signet Healthcare Partners. Jim has over 35 years of healthcare investing and finance experience. He is currently the Chairman of the Board of Bionpharma, Inc; lead director of Knight Therapeutics Inc. (TSX: GUD); and also serves on the Board of Directors of the following Signet portfolio companies: Juno Pharmaceuticals Corp, Chr. Olesen Synthesis A/S, Pharmaceutics International (Pii), RK Pharma, and Ascendia Pharmaceuticals. He also serves on the Board of Hyloris Pharmaceuticals SA (Euronext: HYL) and Cerium Pharmaceuticals. Prior portfolio company Boards include: Advantice Health (acquired by TA Associates), Arbor Pharmaceuticals, Amarin Corporation, eResearch Technologies Inc., Teligent Inc, and Valera Pharmaceuticals. Prior to founding Signet, Jim was head of principal investment activities and head of investment banking for Gruntal & Co., LLC. While at Gruntal, he made a number of investments including Andrx Corporation, Royce Laboratories (merged with Watson Pharmaceuticals), Lifecell Corporation (now part of AbbVie), Neurocrine Biosciences, and BML Pharmaceuticals (acquired by Endo Pharmaceuticals). Prior to joining Gruntal, he originated and managed private equity investments for the Home Insurance Co., Gruntal’s parent. Earlier in his career, Jim was a senior investment banker at E.F. Hutton & Co. Jim received his Masters of Business Administration from the University of Chicago.